> Products > EASYEF

1. What is EGF?

Epidermal Growth Factor (EGF) is a single-chain polypeptide consisting of 53 amino acids with a molecular weight of about 6,200 Daltons. Six cysteine residues in the sequence of hEGF from three disulfide bonds are required for hEGF to be biologically active.
EGF was first isolated from the submaxillary glands of adult male mice. Human EGF was discovered in human urine as an inhibitor of gastric acid secretion. Today, hEGF has become one of the most attractive growth factors in life sciences as well as biotechnological fields.
Human EGF is a potent stimulator of epithelial and endothelial cells and fibroblast proliferation both in vitro and in vivo, which results in its potential as a promising healing agent for the treatment of various skin and corneal wounds. In dermatology, EGF can be used as a healing agent for skin wounds, such as diabetic ulcers, bed sores, venous stasis ulcers, skin burns and surgical incisions. In ophthalmology, EGF can be utilized as a healing agent for corneal ulcers and ophthalmic surgery, such as corneal transplantation and excimer laser keratectomy, and the prevention of corneal degeneration. It is also a good candidate for the treatment of gastric ulcers because it inhibits gastric acid secretion and regenerates gastric mucosal layer.

2. Mechanism of EGF Action

  1) Re-epithelialization
      EGF promotes epithelial cells to proliferate and move to fill wounds.
  2) Promotion of granulation tissue
      EGF stimulates fibroblasts in dermal tissue to facilitate dermal cells to differentiate and proliferate.
  3) Angiogenesis
      EGF promotes endothelial cells to proliferate to regenerate blood vessels.

3. Key Benefits and Features

  1) First pharmaceutical EGF product to gain worldwide approval in the world
      Currently marketed in Jordan, Vietnam and many other countries
      Highly potent and safe compared with other EGF products
  2) Identical to natural human EGF, ultra-pure and homogeneous
      Manufactured by the innovative and proprietary E.coli expression system
  3) INN (generic name): Nepidermin
      Ref) WHO Drug Information (2008), 22(1):59